Distribution of TMB and neoantigen load across tumour types.

Slides:

Advertisements

Similar presentations

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Advertisements

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

Figure 2 Neoantigen presentation in the tumour microenvironment

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The contribution of research papers by cancer application site on the two sets of cancer clinical practice guidelines, in comparison with the corresponding.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Immunohistochemistry of CD8 (A and B) and PD-L1 (C–F).

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Clinical algorithm of diagnosis and treatment of bone metastasis guideline. Clinical algorithm of diagnosis and treatment of bone metastasis guideline.

(A) WES of CSF-derived ctDNA collected prior to T-DM1 treatment.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.

Progesterone receptor nuclear morphology patterns in breast cancer.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. Programmed cell death ligand-1 (PD-L1) expression of alveolar macrophages. (A)

Recurrence pattern after initial treatment of brain metastases and cause of death. Recurrence pattern after initial treatment of brain metastases and cause.

Therapeutic validation in orthotopic lung PDX. (A).

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Flow chart of the used methodology adapted from Moher et al

The decision tree with the two alternatives.

Choice of the study design (superiority vs non-inferiority design) for postregistration trials comparing different treatments for the same therapeutic.

Detection rate for EGFR mutations in cfDNA.

Mechanism of CTLA-4-induced immunosuppression.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

(A) Number of KRAS mutations detected by mutation concentration by each technology with 100 copies mutant allele frequency. (A) Number of KRAS mutations.

Histological and molecular heterogeneity of triple negative breast cancer (TNBC). Histological and molecular heterogeneity of triple negative breast cancer (TNBC).

Methods distribution among the three EQAs

Changes in haemoglobin over the course of the treatment in a patient with chronic myeloid leukaemia who developed pure red cell aplasia secondary to imatinib.

Clinical courses of patients.

Early lesion analysis to identify potential targets for therapeutic intervention. Early lesion analysis to identify potential targets for therapeutic intervention.

Illustration of common sites of pelvic relapse post-radical cystectomy in patients with ≥pT3 tumours, 9 18 stratified by margins status - (L) positive.

Mean change from baseline in symptom scales and single-item assessments after 6 weeks of alectinib treatment according to (A) the QLQ-C30 and (B) the QLQ-LC13.

Awareness of respondents about the availability or development of specialised services for AYA where adult and paediatric cancer specialists work together.

Programmed cell death ligand-1 (PD-L1) immunohistochemistry for pulmonary adenocarcinoma tissues. Programmed cell death ligand-1 (PD-L1) immunohistochemistry.

Tumour types of patients whose cancers harboured actionable molecular alterations in our series. ACUP, adenocarcinoma with unknown primary. Other: appendix.

Figure 1. Relationships among microsatellite instability (MSI; letter A indicates the group with MSI), high tumour ... Figure 1. Relationships among microsatellite.

Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.

Gender representation of board members in all international societies (reference year: 2016). Gender representation of board members in all international.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

The emerging treatment paradigms for overall management of advanced SQCLC. SQCLC, squamous cell lung cancer; TPS, tumour proportion score; Pembro, pembrolizumab;

Application of 5-aminolevulinic acid (5-ALA) induced fluorescence during resection of a brain metastasis. Application of 5-aminolevulinic acid (5-ALA)

Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Gender representation in all international congresses (reference year 2016). Gender representation in all international congresses (reference year 2016).

Concentration-time profiles of repeated weekly infusions of (A) 720 mg and (B) 990 mg tomuzotuximab measured in individual patients before and at the end.

Proportion of continuous, intermittent, and limited (

Overview of cancer genetics in the SMP1 cohort: lung cancer (A), breast cancer (B), colorectal adenocarcinoma (except mucinous subtype) (C), prostate cancer.

On the left, Euler-Venn diagram of point mutations detected by lbNGS and ttNGS on matched genes from the same patients; on the right, the percentage of.

The 22 study patients: overall survival (first patient enrolled 9 May 2014, last patient enrolled 26 August 2015, censoring date 9 May 2016); primary tumour.

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Immunochemical staining for HMBG3 in normal cervix, CIN III and invasive carcinomas and could show absent staining in normal cervix (A), absent to weak.

Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Overview of important signalling pathways in angiogenesis and antiangiogenic agents. Overview of important signalling pathways in angiogenesis and antiangiogenic.

Treatmentalgorithm for metastatic TNBC patients consideringthe incorporation of PARPis and immunotherapy. *Defined as PD-L1 expression on tumour-infiltratingimmune.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Kaplan-Meier plots of (A) time to first improvement and (B) time to first deterioration in pain in the chest, cough and dyspnoea, according to the 13-Item Quality.

Heterogeneity in the natural history of triple negative breast cancer.

Clinical characteristics at diagnosis of brain metastases.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

(A) Survival curves according to clinical response.

Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. A,

Consort diagram of the study depicting the process of patients’ selection. Consort diagram of the study depicting the process of patients’ selection. A.

Total number of KRAS variants identified and discussed by the Genomics Review Board from all Sarah Cannon Molecular Diagnostics reports. Total number of.

(A) Distribution of dMMR proteins in the entire cohort and per tumour type. (A) Distribution of dMMR proteins in the entire cohort and per tumour type.

Prescribers’ responses rating their level of comfort on a scale of 1–5

Prescribers’ responses rating their level of knowledge/understanding on a scale of 1–5. Prescribers’ responses rating their level of knowledge/understanding.

Meta-analysis of the effect of gender in the overall survival, comparing HRs and 95% CI obtained from multivariate analysis in hospital databases. Meta-analysis.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

Distribution of TMB and neoantigen load across tumour types. Distribution of TMB and neoantigen load across tumour types. (A) TMB and corresponding predicted neoantigen variation across 14 different tumour types. Data derived from Chen et al.26 (B) TMB variation across 30 different tumour classes. Adapted with permission from Springer: Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013;500(7463):415–21;30 Copyright 2013. AD, adenocarcinoma; ALL, acute lymphocytic leukaemia; AML, acute myeloid leukaemia; CLL, chronic lymphocytic leukaemia; SCLC, small cell lung cancer; SQ, squamous cell carcinoma; TMB, tumour mutational burden. Reinhard Büttner et al. ESMO Open 2019;4:e000442 Copyright © European Society for Medical Oncology. All rights reserved.